Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lutz O, Harnisch"'
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 3, Pp 375-386 (2023)
Abstract Duchenne muscular dystrophy (DMD) is a rare genetic disorder caused by decreased or absent dystrophin gene leading to progressive muscle degeneration and weakness in young boys. Disease progression models for the North Star Ambulatory Assess
Externí odkaz:
https://doaj.org/article/eec9b2ee80954fc29c1fa3a1f3337e51
Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy
Autor:
Jessica Wojciechowski, Vivek S. Purohit, Lutz O. Harnisch, Pinky Dua, Beesan Tan, Timothy Nicholas
Publikováno v:
Clinical pharmacology and therapeutics. 112(6)
Myostatin, a negative regulator of skeletal muscle growth, is a therapeutic target in muscle-wasting diseases. Domagrozumab, a humanized recombinant monoclonal antibody, binds myostatin and inhibits activity. Domagrozumab was investigated in a phase
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 46:473-484
Intracerebral hemorrhage (ICH) is a form of stroke characterized by uncontrolled bleeding into the parenchyma of the brain. There is no approved therapy for ICH and it is associated with very poor neurological outcomes with around half of subjects dy
Autor:
Brinda K, Tammara, Lutz O, Harnisch
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
This modeling and simulation exercise aimed to provide dosing recommendations for rivipansel phase III studies in children aged 6–11 years with sickle cell disease (SCD). Pharmacokinetic data from 109 patients aged 12–51 years who received rivipa